Post-earnings recap
Reported
Thu, May 5, 2016
Est. EPS
—
Est. revenue
—
Implied move
—
EPS beat rate
88%
—
Est. EPS
—
Est. Rev
—
Impl. Move
—
PTC Therapeutics reported a larger-than-expected loss per share, which contributed to a slight decline in stock price. The lack of revenue data and guidance may raise concerns among investors about the company's near-term prospects. The stock's 1.29% drop reflects investor caution following the earnings report.
| Metric | Actual | Expected | Surprise |
|---|---|---|---|
| EPS | $-1.22 | N/A | -0.66% |
| Revenue | N/A | N/A | N/A |
Management expressed caution regarding future performance without providing specific guidance. They emphasized their commitment to ongoing projects.
Management did not provide specific revenue guidance for the upcoming quarters.
The company is focusing on ongoing clinical trials and product development.